title: The eradicating Helicobacter pylori infection in duodenal ulcer patients by three short-term triple therapies in China: a multicenter clinical comparative study.
abstract: OBJECTIVE
  This study aimed to compare the 7d triple therapy with 3d and 5d triple therapies, to observe the effect of eradicating Helicobacter pylori (Hp) on treating duodenal ulcers.
  
  
  METHODS
  One hundred and sixteen patients who were confirmed duodenal ulcer active period and Hp positive were enrolled in the study. All the patients were divided into three groups: 3d group (n=39), 5d group (n=37) and 7d control group (n=40). All three groups were provided triple therapy first: rabeprazole, 10mg + furazolidone, 100mg + clarithromycin 250mg, twice a day for three days, five days and seven days, respectively. Then rabeprazole 10mg was provided once a day. Following the treatment, 13C urea breath test was performed to observe the Hp eradication rate. The symptoms of patients such as epigastralgia, burning pain and acidity were evaluated.
  
  
  RESULTS
  The Hp eradication rate was: 3d group 76% (28/37), 5d 89% (31/35) and 7d 91% (32/35). There was no significant difference between 5d and 7d group (p>0.05). But the rate of groups 5d and 7d was significantly higher than group 3d (p<0.05). All the three groups showed an improvement in symptoms such as epigastralgia, burning pain and acidity.
  
  
  CONCLUSIONS
  All three therapy schemes could alleviate symptoms of duodenal ulcer patients efficiently. But as far as eradicating Hp concerned, 5d and 7d therapies were better than 3d.
authors.affiliation: Department of Gastroenterology, Tongji University, Shanghai, China.
authors.forename: Wei-Qi
authors.initials: WQ
authors.lastname: Dai
authors.forename: Yin-Qun
authors.initials: YQ
authors.lastname: Zhou
authors.forename: Ling
authors.initials: L
authors.lastname: Xu
authors.forename: Bin-Fang
authors.initials: BF
authors.lastname: Wang
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Fan
authors.forename: Jian-Ye
authors.initials: JY
authors.lastname: Wu
authors.forename: Chun-Yan
authors.initials: CY
authors.lastname: Wang
authors.forename: Xuan-Fu
authors.initials: XF
authors.lastname: Xu
authors.forename: Chuan-Yong
authors.initials: CY
authors.lastname: Guo
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000897:Anti-Ulcer Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001944:Breath Tests; D016009:Chi-Square Distribution; D002681:China / Q000453:epidemiology; D017291:Clarithromycin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D005260:Female; D005664:Furazolidone / Q000008:administration & dosage* / Q000009:adverse effects; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D064750:Rabeprazole; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D064750:Rabeprazole; D005664:Furazolidone; D017291:Clarithromycin